Existing evidence indicates that it is reasonable for continued use of ACE inhibitor plus ARB combination for proteinuric nephropathies and resistant hypertension [117], and for diabetic nephropathy [107]. This evidence concerns the gene ACE and Hypertension resistant to conventional therapy.